News

Bringing Collaboration to the Horizon Once More

January 03, 2024

UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion

January 02, 2024

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.

Finalizing the European Health Data Space

January 02, 2024

The EHDS aims to increase access to health data, but how will it impact pharma?

Unlucky for Some

January 02, 2024

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

Reimbursement Precipitating Shortages

January 02, 2024

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

The Decline and Fall of the Clinician–Scientist

December 29, 2023

Clinician-Scientists are vital innovation spark plugs, accounting for 40% of Nobel awards in Physiology or Medicine, and two thirds of Big Pharma CSOs.

Replay Signs Exclusive Licensing Agreements with NIH and Miltenyi Biotec for Cell Therapy Development and Manufacturing

December 29, 2023

Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.

Körber and Franz Ziel Tighten Ties

December 28, 2023

Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?

Tome brings $213 Million to the Programmable Genome Editing Party

December 28, 2023

Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.

European Medicines Regulatory Network on Track to Meet Goals

December 27, 2023

The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.